-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
NS2B-NS3-IN-2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/ns2b-ns3-in-2.gif)
| Category | Virus Protease |
| Description | NS2B/NS3-IN-2 is a potent dengue virus (DENV) NS2B/NS3 covalent inhibitor with an IC50 of 6.0 nM and Ki of 0.66 µM. |
Product Information
| Molecular Weight | 463.51 |
| Molecular Formula | C24H21N3O5S |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | NS2B/NS3-IN-2 (compound 23) (150 nM) shows 100% inhibition rate against Dengue virus (DENV). NS2B/NS3-IN-2 (5 µM) shows no cytotoxicity and markedly increases the cell survival rate. |
| Target | IC50: 6.0 nM (NS2B/NS3) |
